Investigating the Lowest Threshold of Vascular Benefits from LDL Cholesterol Lowering with a PCSK9 mAb Inhibitor (Alirocumab) in Patients with Stable Cardiovascular Disease (INTENSITY-HIGH): protocol and study rationale for a randomised, open label, parallel group, mechanistic study.
Paul J CacciottoloMichalis S KostapanosElena Hernan SanchoHolly PaveyFotini KaloyirouEvangelia VamvakaJoanna HelmyAnnette HubschCarmel M McEnieryIan B WilkinsonJoseph CheriyanPublished in: BMJ open (2021)
NCT03355027.